Clasp

ClaspClasp
C

Clasp

Clasp helps healthcare employers build long-term talent pipelines by connecting with clinicians before graduation and tying student loan repayment to tenure.

Website
DR 492020ActiveBoston, USA
Rate
Advertise here

About

Clasp is a company that addresses the healthcare talent shortage by offering a unique model called ROTC (Retention Over Turnover Costs). This model, inspired by the military's early commitment structure, focuses on Loan-Linked Hiring. Clasp connects healthcare employers with aspiring clinicians before they graduate, offering incentives like student loan repayment in exchange for a commitment to work for a specified tenure. This approach aims to reduce turnover costs for healthcare organizations and build stable, long-term talent pipelines.
Frequently asked

What does Clasp do?

Clasp is a company that addresses the healthcare talent shortage by offering a unique model called ROTC (Retention Over Turnover Costs). This model, inspired by the military's early commitment structure, focuses on Loan-Linked Hiring. Clasp connects healthcare employers with aspiring clinicians before they graduate, offering incentives like student loan repayment in exchange for a commitment to work for a specified tenure. This approach aims to reduce turnover costs for healthcare organizations…

What is Clasp's revenue?

StartupHub estimates Clasp's annual revenue at $215.7M (range $108.4M to $440.0M, 42% confidence), based on comparable companies in the sector.

What is Clasp's valuation?

StartupHub estimates Clasp's effective valuation at $1.1B (range $754.0M to $1.4B, 40% confidence), based on comparable companies in the sector.

How much funding has Clasp raised?

Clasp has raised a total of $20M in funding. The most recent round on record is Series B.

Where is Clasp headquartered?

Clasp is headquartered in Boston, Massachusetts, USA.

When was Clasp founded?

Clasp was founded in 2020.

What industry does Clasp operate in?

Clasp operates in Healthcare, Human Resources, Fintech, SaaS.

Comments

No comments yet. Be the first to share your take.